Core Viewpoint - Company Huaheng Biological has announced a significant investment plan of 320 million yuan to establish an "AI Precision Fermentation and Protein Engineering Shared Demonstration Project" to maintain its industry leadership and meet market demands for high-quality, low-cost products [1] Group 1: Investment and Project Details - The investment will fund the construction of new production facilities, including workshops, finished goods warehouses, and office buildings, with a projected construction period of 36 months [1] - The funding will come from the company's own or self-raised funds, aimed at building an intelligent production system [1] Group 2: Financial Performance - In 2024, the company reported revenue of 2.178 billion yuan, a year-on-year increase of 12.37%, but net profit fell by 57.80% to 190 million yuan [2] - The decline in net profit is primarily attributed to price pressures on valine products, which are at historical lows due to intensified market competition [2] - In Q1 2025, revenue grew by 37.20% to 687 million yuan, but net profit decreased by 40.98% to 51.1 million yuan [2] Group 3: Research and Development - The company has consistently increased its R&D expenditure from 30.12 million yuan in 2020 to 124 million yuan in 2024, totaling 395 million yuan over five years [3] - In 2024, the company achieved significant breakthroughs in major projects, advancing its product diversification strategy with key projects like bio-based succinic acid and 1,3-propanediol [3] - The company added 10 invention patents and 8 utility model patents in 2024, bringing the total to 78 invention patents and 77 utility model patents by the end of 2024 [3]

Core Insights - The recent publicity surrounding the chairman of a pharmaceutical company promoting its product, ergothioneine capsules, led to a significant 20% increase in the stock price of its subsidiary, Chuaning Bio [1] - Despite initial market excitement, the price of ergothioneine has drastically decreased from 300,000 yuan per kilogram to below 10,000 yuan due to advancements in synthetic biology and increased competition [1][2] - The company Jinsan Bio has decided to fully commit to promoting ergothioneine, aiming to establish itself as an industry leader by actively creating market demand rather than waiting for trends to develop [2][4] Company Strategy - Jinsan Bio's founder, Ding Wei, emphasizes the importance of innovation and market leadership, stating that to become an industry leader, one must pave new paths and help generate market interest [2][8] - The company has set ambitious sales targets, aiming for a gross merchandise volume (GMV) of 300 million yuan in 2023 and 500 million yuan in 2024, with a monthly GMV exceeding 30 million yuan by 2025 [2][3] - Jinsan Bio has successfully completed a Pre-A round of financing exceeding 100 million yuan, with investments from various funds, indicating strong investor confidence in its business model [2] Product Development and Marketing - Jinsan Bio has developed a range of products including skincare serums, oral capsules, and eye drops, focusing on the health benefits of ergothioneine [10] - The company employs a dual strategy of B2B and B2C, selling raw materials while also marketing consumer products, which has proven effective due to the team's background in consumer goods [4][7] - The marketing strategy includes leveraging online sales channels such as JD, Tmall, and Douyin, with a significant portion of sales coming from live-streaming and private domain traffic [11] Research and Clinical Trials - Jinsan Bio is conducting investigator-initiated trials (IIT) to validate the health benefits of ergothioneine, focusing on its effects on liver function and eye health [5][6] - The decision to pursue IIT is seen as a unique approach in the dietary supplement industry, providing scientific evidence to support the efficacy of their products [6] Industry Context - The decline in raw material prices has led many investors to be cautious about ergothioneine, but Jinsan Bio's proactive approach aims to change this perception and stimulate market growth [2][4] - The company positions itself as a leader in the ergothioneine niche, aiming to create a robust market presence and consumer awareness [8][15]

Core Viewpoint - Haizheng Pharmaceutical (600267) aims to adopt a differentiated strategy focusing on solidifying its industrial foundation, with emphasis on synthetic biology and high-end manufacturing [1] Group 1: Company Overview - Established in 1956, Haizheng Pharmaceutical started with raw materials and has evolved into a comprehensive pharmaceutical enterprise covering the entire value chain from research and production to sales [1] - The company operates a significant production base in Fuyang, Zhejiang, which spans over 1,500 acres and includes various subsidiaries [1] Group 2: Raw Material Business - The raw material segment is a traditional focus for Haizheng, leveraging technological and production scale advantages [2] - The company has developed over a hundred raw material drug varieties, utilizing a fermentation semi-synthesis technology platform [2] - Haizheng is expanding into the health sector, particularly in medical aesthetics and industrial raw materials, to enhance its sales capabilities [2] Group 3: Production Capabilities - Haizheng has established three major production bases in Taizhou, Fuyang, and Nantong, with a complete production line layout [2] - The Fuyang base features 17 independent production lines and adheres to a production philosophy of "pipeline, closed, continuous, and automated" [2] - The base has successfully secured CMO orders from international giants like Merck and continues to advance new product registrations [2] Group 4: Pharmaceutical Formulation Business - Haizheng has achieved a leading position in exporting injectable drugs to the U.S. market, maintaining high GMP standards [3] - The formulation business is primarily managed by its subsidiary, Hanhui Pharmaceutical, which has developed a unique quality management model [3] - Hanhui has successfully completed technology transfers for several original research products, addressing domestic supply shortages [3] Group 5: Animal Health Sector - The animal health segment is a key area of focus, with Haizheng leveraging its bases to create a diverse product matrix for livestock and pets [3] - Haizheng Animal Health has obtained multiple certifications and has several products with significant sales, including a record-breaking domestic deworming drug [3] - The company has a production capacity of 3,000 acres, allowing for strategic positioning in human and animal pharmaceuticals, both domestically and internationally [3]

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文 不构成任何投资建议！转载请注明来源！ 5月20日， 凯赛生物 在投资者互动平台上表示， 目前公司位于山西合成生物产业园的项目建设正在进 行中，受园区配套基础设施规划变动影响，公司年产90万吨生物基聚酰胺项目有所延期， 但项目的一 部分—— 年产5000吨生物基高温聚酰胺生产线 已经建成，可满足目前连续纤维复合材料开发的需求 。 公司在合肥规划建设的 Bio-PPA CFRT生产基地 也已经开始建设。 关于凯赛生物山西合成生物产业园项目 据了解，凯赛生物与山西综改示范区管委会于 2020年10月签署合作协议，合力打造"山西合成生物产业 生态园"，计划 总投资规模为800亿元 ，其中一期投资计划投资450亿元，二期计划投资 350 亿元。 核心项目 包括240万吨玉米深加工项目及 500 万吨 / 年生物发酵液项目、年产 50 万吨生物基戊二胺项 目、年产 90 万吨生物基聚酰胺项目和年产 8 万吨生物基长链二元酸项目（含 4 万吨生物法癸二酸项 目）。达产后产值将达千亿元以上。 项目详情： 凯赛 ...

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金 各方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投 资家，在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 第三届中国合成生物学"科学家+企业家+投资家"大会 SynBio China合成生物学与食品大健康产业大会 中国蛋白生物制造大会 美之原·合成生物学功能护肤大会 美之注·注射医疗美容产业大会 SynBio China合成生物学产学研对接会 SynBio China合成生物学新锐项目路演 聚产业力量、擘画未来 SynBio China第三届中国合成生物学"科学家+企业家+投资家"博览会 将于2025年8月1-2日在 苏州国际博览中心B馆 举办（同期举办 第七届CMC-China博览会 ）！ 本次博览会共包含7个子会议： 诚邀莅临，共襄盛举 展会名称： Synbio China 第三届中国合成生物学"科学家+企业家+投资家"博览会 展会 时间： 2025年8月1-2日 展会 地点： 苏州国际博览中心·B馆 展会 规模： 20000+ 主办单位： synbio深波 支持单位： Synbio ...

医疗美容 2025 年 05 月 21 日 投资评级：看好（首次） 行业走势图 数据来源：聚源 -19% -10% 0% 10% 19% 2024-05 2024-09 2025-01 沪深300 华熙生物通过多次产业革命重塑 HA 产业：从微生物发酵法量产到分子量精准控 制，再到探索合成生物技术精准调控 HA 实现多细胞微环境调控。华熙生物基于 糖生物学进入细胞生物学，探索衰老干预和再生医学的广阔空间。其提出"细 胞衰老本质论"，发现不同分子量 HA 可调控干细胞分化、线粒体活力及 DNA 稳定性，并开发无动物源培养基、细胞上清液等再生医学产品。产业转换能力领 先：华熙生物拥有全球最大的合成生物中试平台、超纯 HA 原料制备能力及全链 路转化生态（研发-原料-品牌），全产业链模式快速打通实验室到市场，HA 市占 率与医美三类械证数量均居行业第一。目前华熙的医美注射三类医疗器械注册证 达到 11 项，爱美客（8 项）、昊海生科（4 项）、艾尔建（9 项）、锦波生物（3 项）， 产品覆盖面部填充、唇部塑形、皮肤改善等多个场景。HA 之外，华熙生物深入 探索其他多糖，如肌肉骨骼中的硫酸软骨素，血液里的肝素等对于细 ...

Core Viewpoint - Huaxi Biological refutes the notion that hyaluronic acid is outdated, emphasizing its leading position in the global market and the importance of scientific integrity in the industry [2][4][7] Group 1: Company Response - Huaxi Biological published an article titled "Concepts Always Reappear, Technology Always Moves Forward" to counter the claims made by several brokerage reports that suggest hyaluronic acid is no longer relevant [2][6] - The company asserts that hyaluronic acid is a key life science material and has been subjected to unfounded criticism, which it aims to correct as an industry leader [3][4] - Huaxi Biological's statement received support from the China Fragrance and Cosmetic Industry Association and the China Aesthetic Medicine Association, highlighting a collective industry stance [3][4] Group 2: Scientific Basis and Product Strategy - The company clarifies that its chairman previously questioned the effectiveness of topical recombinant collagen products, but this was specifically aimed at exaggerated claims regarding their efficacy [6][7] - Huaxi Biological maintains that its strategic focus remains on the development of hyaluronic acid and its applications in various health-related fields, rather than shifting to recombinant collagen as a mainstream technology [7] - The company emphasizes that current scientific evidence does not support recombinant collagen's superiority in managing aging compared to hyaluronic acid [7]

编号：2025-001 | 投资者关系 | 特定对象调研□分析师会议 媒体采访☑业绩说明会 | | --- | --- | | 活动类别 | 新闻发布会路演活动 | | | □现场参观 其他 | | 参与单位名称及 | 通过价值在线以网络方式参与公司 2024 年度暨 2025 年第一季度网上 | | 人员姓名 | 业绩说明会的广大投资者 | | 时间 | 2025 年 5 月 20 日 15：00-16:00 | | 地点 | 价值在线（www.ir-online.cn） | | | 董事长：胡立刚先生 总经理：龚铖先生 | | 上市公司 接待人员姓名 | 董事会秘书：郑彬先生 财务总监：熊毅先生 | | | 独立董事：郭炜先生 | | | 1、请问贵公司 25 年有没有除医药以外的项目收购重组计划？ | | | 答:您好，公司如有应披露的重大事项，将严格按照相关法律法规的规 | | | 定和要求及时履行信息披露义务，感谢您的关注！ | | | 2、公司人乳寡糖产品研究进展如何？ | | | 答：您好，公司与江南大学合作的人乳寡糖项目正在积极推进，力争 | | | 尽快将人乳寡糖产品获批上市。感谢 ...

A股今日（5月20日）全线上扬，市场整体活跃，成交量有所放大；港股亦走高，两大股指均涨超 1%。 中信证券表示，海外订单稳健增长、鸡肉成本下行、人民币贬值、国产宠粮自主品牌整体增长提速、国货 龙头盈利能力持续提升等背景下，2024年、2025年一季度宠物板块业绩持续新高。展望后续，预计海外 需求稳健，国内市场国货替代持续，2025年宠物板块业绩有望持续增长。宠物经济是稀缺赛道，需求韧 性强，国内市场目前仍处"大行业、小龙头"阶段，龙头集中程度有望进一步提升，看好龙头通过产品创 新、品牌和渠道建设不断提升市场份额。 具体来看，A股三大股指盘中发力拉升，创业板指一度涨超1%。截至收盘，沪指涨0.38%报3380.48 点，深证成指涨0.77%报10249.17点，创业板指涨0.77%报2048.46点，北证50指数涨1.22%，沪深北 三市合计成交12114亿元，较昨日（5月19日）增加923亿元。 场 内 超 3800 股 飘 红 ， 宠 物 经 济 概 念 爆 发 ， 天 元 宠 物 （ 301335 ） 20% 涨 停 创 出 新 高 ， 路 斯 股 份 （832419）一度涨停亦创新高；合成生物概念再度活 ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 近日， 上海肆芃科技有限公司 （以下简称"肆芃科技"）宣布完成数千万元Pre-A+轮融资，本轮融资由上海国投孚腾资本投资，熙桥资本担任独家财务顾 问。 所筹资金将用于加速生物基材料产品的商业化落地及三代碳源生物制造平台建设。 值得一提的是，2024年10月， 肆芃科技完成近亿元Pre-A轮融资，由国投创合领投、如皋科创投跟投，熙桥资本担任独家财务顾问。 所筹资金将用于进 一步加强生物制造产品量产及商业化推广。 肆芃科技成立于2022年，是一家 专注于材料合成生物学的生物制造企业 。公司创始团队深耕行业二十余年， 在生物基材料领域拥有丰富研发生产经验 ，曾完成多项"卡脖子"技术突破并实现多家行业龙头企业的核心产品开发，具备多个生物制造产品的产业化放大落地成功经历。同时也 是上海交通大学 科技成果转化的代表性企业。 肆芃科技依托智能生物制造平台及高性能材料应用开发平台致力于研发生产具有全球竞争力的生物基产品。 生物制造平台方面 ，公司打破海外技术垄断，已完成多个生物基多元醇/酸 ...